Australasian Journal of Dermatology最新文献_第2页

The Use of Etanercept in the Palliative Treatment of a Patient With Generalised Bullous Fixed Drug Eruption. 依那西普在广泛性大疱性固定药疹的姑息治疗中的应用。

IF 1.8 4区医学

Australasian Journal of Dermatology Pub Date : 2025-09-02 DOI: 10.1111/ajd.14577

Olga Pawlik, Timothy Cowan, Andrew Miller

引用次数: 0

Safety and Efficacy of Angiotensin Receptor Antagonists in Recessive Dystrophic Epidermolysis Bullosa. 血管紧张素受体拮抗剂治疗隐性营养不良大疱性表皮松解症的安全性和有效性。

IF 1.8 4区医学

Australasian Journal of Dermatology Pub Date : 2025-09-02 DOI: 10.1111/ajd.14594

Joseph Joseph, Alexandra Murray, Kelvin Truong, Artiene Tatian

{"title":"Safety and Efficacy of Angiotensin Receptor Antagonists in Recessive Dystrophic Epidermolysis Bullosa.","authors":"Joseph Joseph, Alexandra Murray, Kelvin Truong, Artiene Tatian","doi":"10.1111/ajd.14594","DOIUrl":"10.1111/ajd.14594","url":null,"abstract":"Recessive dystrophic epidermolysis bullosa (RDEB) is an inherited progressive blistering skin disorder caused by mutations in the COL7A1 gene. Chronic wounds lead to cycles of scarring and healing, causing severe functional deformities. Losartan is an angiotensin II type 1 receptor (AT1R) antagonist that has been shown to have antifibrotic activity via inhibiting the production of transforming growth factor beta (TGF-B) and has a favourable safety profile in children. In this systematic review, there were five studies found, with a total of 59 patients including case series, case-control and an open label phase 2 clinical trial. These studies have demonstrated the safety of losartan with no significant adverse effects such as hypotension, hyperkalaemia and hypersensitivity. They have also demonstrated evidence of efficacy utilising subjective assessments and objective criteria such as the Birmingham Epidermolysis Bullosa Severity score (BEBS) and Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI). Although safe and effective, further clinical trials are required to fully elucidate the role of this treatment; whether this approach should be standardised across the RDEB patient cohort is yet to be determined from the current evidence. Trial Registration: PROSPERO ID: CRD42024557126.","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144940285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Case Series: Scabies Complicating Dupilumab Therapy for Atopic Dermatitis. 病例系列：疥疮并发杜匹单抗治疗特应性皮炎。

IF 1.8 4区医学

Australasian Journal of Dermatology Pub Date : 2025-08-30 DOI: 10.1111/ajd.14589

Madeleine Louise Kelly, Robert M Miller

引用次数: 0

Effectiveness of Biologic Therapy in Hidradenitis Suppurativa: Real-World Clinical Outcomes and Lipid Profile Evaluation. 化脓性汗腺炎生物治疗的有效性：真实世界临床结果和脂质评估。

IF 1.8 4区医学

Australasian Journal of Dermatology Pub Date : 2025-08-26 DOI: 10.1111/ajd.14592

R Cascio Ingurgio, A Alfano, E Matteodo, M Stark, M Valenti, A Narcisi, A Costanzo, D F Murrell

{"title":"Effectiveness of Biologic Therapy in Hidradenitis Suppurativa: Real-World Clinical Outcomes and Lipid Profile Evaluation.","authors":"R Cascio Ingurgio, A Alfano, E Matteodo, M Stark, M Valenti, A Narcisi, A Costanzo, D F Murrell","doi":"10.1111/ajd.14592","DOIUrl":"https://doi.org/10.1111/ajd.14592","url":null,"abstract":"Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with systemic implications. While biologic therapies have demonstrated efficacy in controlling cutaneous lesions, their systemic effects, particularly on lipid metabolism as a marker of systemic inflammation, are less understood.Objectives: To evaluate the impact of biologic therapy on clinical severity and lipid profiles in HS patients in a real-world setting, comparing outcomes between Early and Late Responders at Week 24 ± 4.Methods: Twenty-four patients with moderate-to-severe HS on biologic therapy were monitored prospectively at Baseline, Week 24 ± 4, Week 52 and Week 104. Clinical parameters (IHS4, A/N, HS-IGA) and lipid profiles (cholesterol, triglycerides) were analysed. Patients were categorised as Early (IHS4 ≤ 10) or Late Responders (IHS4 ≥ 11) at Week 24 ± 4. Statistical analysis included t-tests; significance was set at p < 0.05.Results: Early Responders showed significant clinical improvement and reductions in lipid levels, suggesting a systemic anti-inflammatory effect of therapy. However, lipid reductions did not reach statistical significance (p > 0.05); likely due to the small sample size. Late Responders demonstrated less pronounced changes.Conclusions: Biologic therapy appears to improve both clinical and systemic inflammatory markers in HS, highlighting the value of metabolic monitoring in routine care.","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144940344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Characterising Alternative Diagnoses to Psoriatic Arthritis in a Rheumatology-Dermatology Combined Clinic. 风湿病-皮肤病联合临床银屑病关节炎的另类诊断特征

IF 1.8 4区医学

Australasian Journal of Dermatology Pub Date : 2025-08-21 DOI: 10.1111/ajd.14585

Ugochukwu Kingsley Odega, Wilson Omesiete, Adam Carlson, R Hal Flowers

{"title":"Characterising Alternative Diagnoses to Psoriatic Arthritis in a Rheumatology-Dermatology Combined Clinic.","authors":"Ugochukwu Kingsley Odega, Wilson Omesiete, Adam Carlson, R Hal Flowers","doi":"10.1111/ajd.14585","DOIUrl":"https://doi.org/10.1111/ajd.14585","url":null,"abstract":"Background: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis involving axial and peripheral joints and tendons that affects a subset of patients with psoriasis (PsO). PsA can be a debilitating disease and warrants prompt rheumatologic evaluation and management. The diagnosis of PsA can be challenging for the practising dermatologist as there is often an overlap in the symptoms of PsA and non-inflammatory musculoskeletal conditions such as osteoarthritis, tendonitis and myofascial pain.Aims: The primary aim of the study is to examine psoriasis patients seen at our tertiary institution's combined rheum-derm clinic for a concern for PsA, specifically examining the revised diagnosis and the joint symptom similarities to psoriatic arthritis.Methods and material: We performed a retrospective chart review of patients referred to the rheumatology-dermatology clinic (RDC) at our institution between November 2019 and March 2022. Our review included 242 patients, of which 34 (14%) were psoriasis patients specifically referred due to suspicion for PsA. Each patient underwent a comprehensive rheumatic evaluation, including history, physical examination, laboratory tests and imaging as needed.Results: Fourteen (41.2%) of the 34 patients referred for suspected PsA were diagnosed with non-inflammatory musculoskeletal conditions, primarily mechanical joint pain. Stiffness and/or swelling were significantly more common among patients with confirmed PsA.Conclusions: These findings underscore the importance of thorough evaluation of musculoskeletal symptoms, particularly stiffness and swelling, in patients with psoriasis. Improving education on distinguishing non-inflammatory musculoskeletal conditions may enhance diagnostic accuracy and optimise referral practices.","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144940300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Breast and Nipple Dermatoses During Lactation. 哺乳期乳房和乳头皮肤病。

IF 1.8 4区医学

Australasian Journal of Dermatology Pub Date : 2025-08-15 DOI: 10.1111/ajd.14586

Hamish Moore, Annabel Stevenson

引用次数: 0

Epidemiology and Surveillance of Keratinocyte and Non-Keratinocyte Cancers in Paediatric Solid Organ Transplant Recipients: A Narrative Review. 儿童实体器官移植受者角化细胞和非角化细胞癌的流行病学和监测：一项叙述性综述。

IF 1.8 4区医学

Australasian Journal of Dermatology Pub Date : 2025-08-15 DOI: 10.1111/ajd.14588

James Gaston, Benjamin S Daniel

引用次数: 0

Erythrokeratodermia Variabilis et Progressiva With Compound Heterozygous ABCA12 Variants 伴复合杂合ABCA12变异体的进展性红细胞角化病。

IF 1.8 4区医学

Australasian Journal of Dermatology Pub Date : 2025-08-13 DOI: 10.1111/ajd.14540

Ying Yang, Jingwen Yang, Wenxian Li, Jing Lin, Fang Yang

引用次数: 0

Comment on: Rituximab for the Management of an Australian Cohort of Treatment Refractory Mucous Membrane Pemphigoid 评论：利妥昔单抗用于治疗难治性粘膜类天疱疮的澳大利亚队列。

IF 1.8 4区医学

Australasian Journal of Dermatology Pub Date : 2025-08-13 DOI: 10.1111/ajd.14542

Chenghong Xu, Yifeng Wang

引用次数: 0

Time to Recognise Psoriasis as a Cardiovascular Risk Modifier in National Guidance. 是时候在国家指南中承认牛皮癣是心血管风险调节剂了。

IF 1.8 4区医学

Australasian Journal of Dermatology Pub Date : 2025-08-13 DOI: 10.1111/ajd.14587

Annika Smith, John Frew

引用次数: 0